Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Based on these results, further clinical development of MEDI4166 as a dual-targeted therapy for patients with type 2 diabetes who are at risk for cardiovascular disease was discontinued
Analysts talk about an obesity gold rush and believe that the GLP-1 market could reach $150 billion by 2031 (a figure similar to the profits of the worlds largest oil company or of cancer drugs)
PMID: 2271479 External authority link: pubchem.ncbi.nlm.nih.gov Search AOD-9604 for molecular data DISCLAIMER All products supplied by Ascend Peptides UK are intended strictly for research purposes only
doi:10.1042/bj2690001
US$ 20.56
US$ 22.47
US$ 22.07
US$ 28.79
US$ 27.45
US$ 27.86
US$ 25.48
US$ 24.99
US$ 26.74
US$ 20.38
